Clinical Trial Update: Safety, Tolerability and Immunogenicity of Three Doses of Novartis Meningococcal B Vaccine When Administered to Healthy At-risk Adults [Phase 2]

View source ↗

Summary

Phase 2 study evaluating safety, tolerability, and immunogenicity of three doses of the Novartis Meningococcal B Vaccine in healthy at-risk adults, with results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningococcal Disease

Drugs mentioned

• Novartis Meningococcal B Vaccine (Meningococcal B vaccine)

Snippet

Sponsor: Novartis Vaccines | Conditions: Meningococcal Disease | Phase 2 | Status: COMPLETED | Results posted: 2011-07-08